Cholesterol and Coronary Heart Disease: Screening and Treatment

Overview

Journal Qual Health Care

Specialty Health Services

Date 1999 May 29

PMID 10339027

Citations 6

Authors

S Ebrahim

G D Smith

C McCabe

N Payne

M Pickin

T A Sheldon

F Lampe

F Sampson

S Ward

G Wannamthee

Affiliations

Soon will be listed here.

Citing Articles

Statins for the primary prevention of cardiovascular disease.

Taylor F, Huffman M, Macedo A, Moore T, Burke M, Davey Smith G Cochrane Database Syst Rev. 2013; (1):CD004816.

PMID: 23440795 PMC: 6481400. DOI: 10.1002/14651858.CD004816.pub5.

Statins for the primary prevention of cardiovascular disease.

Taylor F, Ward K, Moore T, Burke M, Davey Smith G, Casas J Cochrane Database Syst Rev. 2011; (1):CD004816.

PMID: 21249663 PMC: 4164175. DOI: 10.1002/14651858.CD004816.pub4.

Differential associations between actual and expected GP practice prescribing rates for statins, ACE inhibitors, and beta-blockers: a cross-sectional study in England.

Ward P, Noyce P, St Leger A Ther Clin Risk Manag. 2008; 1(1):61-8.

PMID: 18360545 PMC: 1661602. DOI: 10.2147/tcrm.1.1.61.53599.

How equitable are GP practice prescribing rates for statins?: an ecological study in four primary care trusts in North West England.

Ward P, Noyce P, St Leger A Int J Equity Health. 2007; 6:2.

PMID: 17386118 PMC: 1847516. DOI: 10.1186/1475-9276-6-2.

Dietary fat intake and prevention of cardiovascular disease: systematic review.

Hooper L, Summerbell C, Higgins J, Thompson R, Capps N, Smith G BMJ. 2001; 322(7289):757-63.

PMID: 11282859 PMC: 30550. DOI: 10.1136/bmj.322.7289.757.

References

Irvine M, Logan A . Is knowing your cholesterol number harmful?. J Clin Epidemiol. 1994; 47(2):131-45. DOI: 10.1016/0895-4356(94)90018-3. View

Elton P, Ryman A, Hammer M, Page F . Randomised controlled trial in northern England of the effect of a person knowing their own serum cholesterol concentration. J Epidemiol Community Health. 1994; 48(1):22-5. PMC: 1059887. DOI: 10.1136/jech.48.1.22. View

Gregory L, Duh S, Christenson R . Eight compact analysis systems evaluated for measuring total cholesterol. Clin Chem. 1994; 40(4):579-85. View

de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin J, Monjaud I . Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 1994; 343(8911):1454-9. DOI: 10.1016/s0140-6736(94)92580-1. View

Collins R, Macmahon S . Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull. 1994; 50(2):272-98. DOI: 10.1093/oxfordjournals.bmb.a072892. View

Insua J, Sacks H, Lau T, Lau J, Reitman D, Pagano D . Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med. 1994; 121(5):355-62. DOI: 10.7326/0003-4819-121-5-199409010-00008. View

Neil H, Roe L, Godlee R, Moore J, Clark G, Brown J . Randomised trial of lipid lowering dietary advice in general practice: the effects on serum lipids, lipoproteins, and antioxidants. BMJ. 1995; 310(6979):569-73. PMC: 2548942. DOI: 10.1136/bmj.310.6979.569. View

Hilton S, Rink E, Fletcher J, Sibbald B, Freeling P, Szczepura A . Near patient testing in general practice: attitudes of general practitioners and practice nurses, and quality assurance procedures carried out. Br J Gen Pract. 1994; 44(389):577-80. PMC: 1239082. View

Anderson J, Johnstone B . Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. 1995; 333(5):276-82. DOI: 10.1056/NEJM199508033330502. View

10.

Law M, Tang J . An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med. 1995; 155(18):1933-41. View

11.

Shepherd J, Cobbe S, Ford I, Isles C, LORIMER A, Macfarlane P . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333(20):1301-7. DOI: 10.1056/NEJM199511163332001. View

12.

Byington R, Jukema J, Salonen J, Pitt B, Bruschke A, Hoen H . Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation. 1995; 92(9):2419-25. DOI: 10.1161/01.cir.92.9.2419. View

13.

Pedersen T, Kjekshus J, Berg K, Olsson A, Wilhelmsen L, Wedel H . Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation. 1996; 93(10):1796-802. DOI: 10.1161/01.cir.93.10.1796. View

14.

Ramsay L, Haq I, Jackson P, Yeo W, Pickin D, Payne J . Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet. 1996; 348(9024):387-8. DOI: 10.1016/s0140-6736(96)05516-x. View

15.

Avins A, Browner W . Lowering risk without lowering cholesterol: implications for national cholesterol policy. Ann Intern Med. 1996; 125(6):502-6. DOI: 10.7326/0003-4819-125-6-199609150-00012. View

16.

Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335(14):1001-9. DOI: 10.1056/NEJM199610033351401. View

17.

Jonsson B, Johannesson M, Kjekshus J, Olsson A, Pedersen T, Wedel H . Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J. 1996; 17(7):1001-7. DOI: 10.1093/oxfordjournals.eurheartj.a014994. View

18.

Morris J . Exercise versus heart attack: questioning the consensus?. Res Q Exerc Sport. 1996; 67(2):216-20. DOI: 10.1080/02701367.1996.10607947. View

19.

Neil H, Silagy C, Lancaster T, Hodgeman J, Vos K, Moore J . Garlic powder in the treatment of moderate hyperlipidaemia: a controlled trial and meta-analysis. J R Coll Physicians Lond. 1996; 30(4):329-34. PMC: 5401602. View

20.

Ul Haq I, Ramsay L, Pickin D, Yeo W, Jackson P, Payne J . Lipid-lowering for prevention of coronary heart disease: what policy now?. Clin Sci (Lond). 1996; 91(4):399-413. DOI: 10.1042/cs0910399. View